Logo image of TOVX

THERIVA BIOLOGICS INC (TOVX) Stock Fundamental Analysis

NYSEARCA:TOVX - NYSE Arca - US87164U5083 - Common Stock - Currency: USD

0.56  +0.04 (+8.21%)

After market: 0.574 +0.01 (+2.5%)

Fundamental Rating

1

Overall TOVX gets a fundamental rating of 1 out of 10. We evaluated TOVX against 562 industry peers in the Biotechnology industry. TOVX has a bad profitability rating. Also its financial health evaluation is rather negative. TOVX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

TOVX had negative earnings in the past year.
TOVX had a negative operating cash flow in the past year.
TOVX had negative earnings in each of the past 5 years.
TOVX had a negative operating cash flow in each of the past 5 years.
TOVX Yearly Net Income VS EBIT VS OCF VS FCFTOVX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M

1.2 Ratios

With a Return On Assets value of -72.57%, TOVX is not doing good in the industry: 66.37% of the companies in the same industry are doing better.
The Return On Equity of TOVX (-134.55%) is worse than 61.21% of its industry peers.
Industry RankSector Rank
ROA -72.57%
ROE -134.55%
ROIC N/A
ROA(3y)-44.56%
ROA(5y)-63.19%
ROE(3y)-72.49%
ROE(5y)-81.87%
ROIC(3y)N/A
ROIC(5y)N/A
TOVX Yearly ROA, ROE, ROICTOVX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800 -1K

1.3 Margins

TOVX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TOVX Yearly Profit, Operating, Gross MarginsTOVX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

3

2. Health

2.1 Basic Checks

The number of shares outstanding for TOVX has been reduced compared to 1 year ago.
TOVX has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, TOVX has a worse debt to assets ratio.
TOVX Yearly Shares OutstandingTOVX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
TOVX Yearly Total Debt VS Total AssetsTOVX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

TOVX has an Altman-Z score of -14.73. This is a bad value and indicates that TOVX is not financially healthy and even has some risk of bankruptcy.
TOVX has a worse Altman-Z score (-14.73) than 81.49% of its industry peers.
A Debt/Equity ratio of 0.00 indicates that TOVX is not too dependend on debt financing.
TOVX has a Debt to Equity ratio of 0.00. This is comparable to the rest of the industry: TOVX outperforms 44.84% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -14.73
ROIC/WACCN/A
WACCN/A
TOVX Yearly LT Debt VS Equity VS FCFTOVX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

2.3 Liquidity

A Current Ratio of 2.15 indicates that TOVX has no problem at all paying its short term obligations.
TOVX has a worse Current ratio (2.15) than 74.38% of its industry peers.
TOVX has a Quick Ratio of 2.15. This indicates that TOVX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 2.15, TOVX is doing worse than 72.42% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.15
Quick Ratio 2.15
TOVX Yearly Current Assets VS Current LiabilitesTOVX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 7.87% over the past year.
EPS 1Y (TTM)7.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%61.19%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

TOVX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 16.36% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y16.55%
EPS Next 2Y34.44%
EPS Next 3Y21.61%
EPS Next 5Y16.36%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
TOVX Yearly Revenue VS EstimatesTOVX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 100M 200M 300M
TOVX Yearly EPS VS EstimatesTOVX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -1K -2K -3K -4K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TOVX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TOVX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TOVX Price Earnings VS Forward Price EarningsTOVX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TOVX Per share dataTOVX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -10 -20

4.3 Compensation for Growth

TOVX's earnings are expected to grow with 21.61% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y34.44%
EPS Next 3Y21.61%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for TOVX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

THERIVA BIOLOGICS INC

NYSEARCA:TOVX (5/13/2025, 5:59:05 PM)

After market: 0.574 +0.01 (+2.5%)

0.56

+0.04 (+8.21%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-05 2025-05-05
Earnings (Next)08-11 2025-08-11
Inst Owners16.36%
Inst Owner Change-0.04%
Ins Owners0.48%
Ins Owner Change0%
Market Cap1.56M
Analysts82.86
Price Target6.12 (992.86%)
Short Float %2.67%
Short Ratio0.07
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)21.16%
Min EPS beat(2)-6.82%
Max EPS beat(2)49.15%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)42.62%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.08
P/tB 0.91
EV/EBITDA N/A
EPS(TTM)-29.25
EYN/A
EPS(NY)-5.63
Fwd EYN/A
FCF(TTM)-6.09
FCFYN/A
OCF(TTM)-6.09
OCFYN/A
SpS0
BVpS6.86
TBVpS0.61
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -72.57%
ROE -134.55%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-44.56%
ROA(5y)-63.19%
ROE(3y)-72.49%
ROE(5y)-81.87%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0.73%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.15
Quick Ratio 2.15
Altman-Z -14.73
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)94.56%
Cap/Depr(5y)59.96%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)7.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%61.19%
EPS Next Y16.55%
EPS Next 2Y34.44%
EPS Next 3Y21.61%
EPS Next 5Y16.36%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y9.36%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y11.77%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y10.84%
OCF growth 3YN/A
OCF growth 5YN/A